10,695 results match your criteria Antiphospholipid Syndrome


Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study.

Front Immunol 2019 5;10:376. Epub 2019 Mar 5.

Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.

Is it well-known that one of the major drawbacks of Lupus Anticoagulant (LA) test is their sensitivity to anticoagulant therapy, due to the coagulation based principle. In this study we aimed to assess the reproducibility of LA testing and to evaluate the performance of solid assay phosphatidylserine/prothrombin (aPS/PT) antibodies. We included 60 patients that fulfilled the following inclusion criteria: (I) diagnosis of thrombotic antiphospholipid syndrome (APS); (II) patients with thrombosis and (a) inconstant previous LA positivity and/or (b) positivity for antiphospholipid antibodies (aPL) at low-medium titers [defined as levels of anti-β2Glycoprotein-I or anticardiolipin (IgG/IgM) 10-30 GPL/MPL] with no previous evidence of LA positivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411647PMC

New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report.

Medicina (Kaunas) 2019 Mar 17;55(3). Epub 2019 Mar 17.

IRCCS Centro Neurolesi "Bonino-Pulejo", 98123 Messina, Italy.

Ischemic stroke is a complex multifactorial disorder. Anticoagulation is a growing research area, with the main goal of preventing systemic embolization and stroke. We report the case of a 41-year-old woman with antiphospholipid syndrome who was unsuccessfully treated with Dabigatran, a new oral anticoagulant, as she developed a major stroke involving the right carotid artery, due to deep venous thrombosis with pulmonary embolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicina55030071DOI Listing

Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations.

Sci Rep 2019 Mar 14;9(1):4530. Epub 2019 Mar 14.

Centre de Recherche du CHU de Québec - Université Laval, Département de microbiologie et immunologie, Faculté de Médecine de l'Université Laval, Québec, Qc, Canada.

Mitochondria are organelles that govern energy supply and control cell death. Mitochondria also express bacterial features, such as the presence of inner membrane cardiolipin and a circular genome rich in hypomethylated CpG motifs. While mitochondrial extrusion by damaged organs or activated cells is thought to trigger innate immunity, it is unclear whether extracellular mitochondria also stimulate an adaptive immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-40900-3DOI Listing
March 2019
1 Read

Interleukin-17/Interleukin-21 and Interferon-g producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome.

Haematologica 2019 Mar 14. Epub 2019 Mar 14.

University of Florence;

Systemic lupus erythematosus is frequently associated with antiphospholipid syndrome. Patients with lupus-antiphospholipid syndrome are characterized by recurrent arterial/venous thrombosis, miscarriages, and persistent presence of autoantibodies against phospholipid-binding proteins, such as β2-Glycoprotein I. We investigated the cytokine production induced by β2-Glycoprotein I in activated T cells that infiltrate in vivo atherosclerotic lesions of lupus-antiphospholipid syndrome patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.209536DOI Listing
March 2019
1 Read

Chronic spontaneous coronary artery dissection in association with antiphospholipid syndrome presenting as stable angina.

BMJ Case Rep 2019 Mar 14;12(3). Epub 2019 Mar 14.

Department of Cardiology, University Hospital Limerick, Limerick, Ireland.

A 52-year-old man presented to our cardiology service for an elective diagnostic coronary angiogram for risk stratification in the context of stable angina. He was diagnosed with antiphospholipid syndrome 2 years prior and had three known thrombotic episodes in the form of a stroke, retinal artery occlusion and deep vein thrombosis. Our initial differential was atherosclerotic coronary artery disease, however, coronary angiography demonstrated a dominant right coronary artery with a long segment of chronic spontaneous dissection distally but with thrombolysis in myocardial infarction III flow. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-227674DOI Listing
March 2019
1 Read

Anti-βGPI antibodies enhance atherosclerosis in ApoE-deficient mice.

Biochem Biophys Res Commun 2019 Mar 11. Epub 2019 Mar 11.

Department of Clinical Laboratory and Hematology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, PR China.

Accelerated atherosclerosis often occurs in patients with antiphospholipid syndrome (APS), and auto-antibodies to β glycoprotein I (anti-βGPI) are confirmed as pathogenic antibodies to APS. Our previous studies have demonstrated that the conversion of mouse peritoneal macrophages into foam cells could be enhanced by co-existence of βGPI and anti-βGPI IgG, but this phenomenon has not been explored in vivo. Here, we present a mouse model to observe the effect of anti-βGPI IgG in the development of atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.03.020DOI Listing
March 2019
1 Read

Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction.

PLoS One 2019 14;14(3):e0212614. Epub 2019 Mar 14.

Rouen University Hospital, Department of Internal Medicine, Rouen, France.

Antiphospholipid antibodies (aPL) promote endothelial dysfunction, inflammation and procoagulant state. We investigated the effect of hydroxychloroquine (HCQ) on prothrombotic state and endothelial function in mice and in human aortic endothelial cells (HAEC). Human aPL were injected to C57BL/6 mice treated or not with HCQ. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212614PLOS
March 2019
1 Read

[Systemic lupus erythematosus. Antiphospholipid syndrome].

Rev Prat 2018 Apr;68(4):e165-e175

Service de médecine interne, hôpital Saint-Antoine (AP-HP), Sorbonne Université, Paris, France.

View Article

Download full-text PDF

Source
April 2018
1 Read

Circulating Plasmablasts Contribute to Antiphospholipid Antibody Production, Associated with Type I Interferon Upregulation.

J Thromb Haemost 2019 Mar 12. Epub 2019 Mar 12.

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University.

Background/objective: Antiphospholipid antibodies (aPL) are pathogenic autoantibodies in antiphospholipid syndrome (APS). This study aimed to clarify the mechanism of aPL production.

Methods: T cell and B cell subsets were evaluated in peripheral blood mononuclear cells (PBMCs) of 26 primary APS (PAPS), 19 systemic lupus erythematosus-associated APS (SLE/APS) patients and 10 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14427DOI Listing
March 2019
1 Read

Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome.

Front Immunol 2019 25;10:199. Epub 2019 Feb 25.

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398508PMC
February 2019

Brain stem infarction in a 6-year-old boy with Down syndrome.

Brain Dev 2019 Mar 8. Epub 2019 Mar 8.

Department of Pediatrics, St Mary's Hospital, Japan; Research Center for Children and Research Center for Rett Syndrome, St Mary's Hospital, Japan. Electronic address:

Infarct locations in children with arterial ischemic stroke have primarily been reported to be lobar or in the basal ganglia, and those in patients with Down syndrome (DS) and antiphospholipid syndrome (APS) are typically wide and multiple. No solitary brain stem infarctions have ever been reported in children with DS until now. Here, we report a case of brain stem infarction in a 6-year-old boy with DS who had no cardiac, renal, or intestinal complications. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03877604183064
Publisher Site
http://dx.doi.org/10.1016/j.braindev.2019.02.013DOI Listing
March 2019
3 Reads

Impact of extractable nuclear antigen, anti-double stranded DNA, antiphospholipid antibody, and anticardiolipin antibody positivity on obstetrical complications and pregnancy outcomes.

Hum Antibodies 2019 Feb 25. Epub 2019 Feb 25.

Department of Biostatistics, Hacettepe University, Ankara, Turkey.

Background: Extractable nuclear antigen (ENA) and anti-double stranded DNA (anti-dsDNA) positivity and related diseases like systemic lupus erythematosus, Sjögren syndrome, and other autoimmune diseases are known to be associated with obstetrical complications and poor perinatal outcomes.

Objective: To demonstrate the importance of ENA, anti-dsDNA, antiphospholipid (APL), and anticardiolipin (ACL) antibody positivity on pregnancy outcomes.

Methods: Ninety one pregnant women with known ENA, anti-dsDNA, APL IgG and IgM, and ACL IgG and IgM antibody positivity were retrospectively compared with 91 randomly selected pregnant woman in terms of obstetrical complications and pregnancy outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/HAB-180359DOI Listing
February 2019
1 Read

Cerebellar Atrophy and Neurocognitive Disorder as Primary Presentation of Antiphospholipid Syndrome in a Young Male.

Kans J Med 2019 Feb 26;12(1):22-23. Epub 2019 Feb 26.

University of Kansas School of Medicine-Wichita, Department of Internal Medicine.

View Article

Download full-text PDF

Source
February 2019
1 Read

Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: A systematic review and Meta-analysis: Comment.

J Thromb Haemost 2019 Mar 8. Epub 2019 Mar 8.

CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, France.

In a recent article (1), Elsebaie MA et al. performed a systematic review on direct oral anticoagulants (DOACs) use in venous thromboembolism (VTE) and thrombophilia. In the subgroup of antiphospholipid syndrome (APS) patients and after exclusion of recurrent arterial events, the meta-analysis of six studies (Re-COVER, RE-COVER II, RE-MEDY, EINSTEIN-DVT, EINSTEIN-PE, HOKUSAI VTE, RAPS, TRAPS) suggested that no statistically significant differences were observed between DOACs and warfarin for prevention of recurrent VTE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14422DOI Listing
March 2019
1 Read

Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab.

Autoimmun Rev 2019 Mar 4. Epub 2019 Mar 4.

Cardiac Surgery Unit, Department of Cardiac, Thoracic and Vascular Sciences, University Hospital of Padua, Via Giustiniani, 2, 35, 128 Padua, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.015DOI Listing
March 2019
2 Reads

High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant.

Blood Adv 2019 Mar;3(5):769-776

Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Lupus anticoagulant (LA) has been associated with pregnancy complications and pregnancy loss. Identification of predictive factors could aid in deciding on therapeutic management. To identify risk factors for adverse pregnancy outcomes in high-risk women with persistently positive LA, we prospectively followed 82 women of childbearing age, of whom 23 had 40 pregnancies within the Vienna Lupus Anticoagulant and Thrombosis Study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018026948DOI Listing
March 2019
3 Reads

Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience.

J Thromb Thrombolysis 2019 Mar 5. Epub 2019 Mar 5.

Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, 1305 York Avenue 7th Floor, New York, NY, 10021, USA.

Patients with primary or secondary antiphospholipid syndrome (APS) have an increased risk of recurrent venous, arterial thrombosis and pregnancy complications. Therefore, determining thrombotic risk is important when individualizing antithrombotic therapy in patients with APS. To identify thrombotic risk factors in a cohort of APS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01836-7DOI Listing
March 2019
2 Reads

Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy.

Tex Heart Inst J 2019 02 1;46(1):48-52. Epub 2019 Feb 1.

Thrombotic microangiopathic syndromes are characterized by thrombus formation leading to microangiopathic hemolytic anemia, thrombocytopenia, and end-organ injury that most often affects the kidney and brain. Patients with thrombotic microangiopathy can also present with cardiac involvement, which has been shown to worsen their prognosis. We describe the case of a 46-year-old woman who presented with acute congestive heart failure as a manifestation of catastrophic antiphospholipid syndrome, which is characterized by rapidly progressing multiorgan involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14503/THIJ-17-6472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379002PMC
February 2019
2 Reads

Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases.

Semin Arthritis Rheum 2019 Feb 11. Epub 2019 Feb 11.

Reproductive Medicine Unit, Obstetric Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Background: No absolute data on the treatment of antiphospholipid antibodies (aPL) related to refractory obstetric complications exist to date. TNF-α play a major role in this disorder.

Objective: To assess the effectiveness of TNF-α blockers in 18 aPL-positive women with recurrent infertility after therapy with low-molecular-weight heparin (LMWH) plus aspirin (LDA) plus hydroxychloroquine (HCQ). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2019.02.006DOI Listing
February 2019
2 Reads

Low molecular weight heparin monotherapy for recurrent abortion with antiphospholipid system: A protocol of a systematic review.

Medicine (Baltimore) 2019 Feb;98(8):e14619

Department of Gynecology, First Affiliated Hospital of Jiamusi University, Jiamusi, China.

Background: Previous clinical studies reported low molecular weight heparin (LMWH) monotherpay has been utilized for the treatment of recurrent abortion (RCA) with antiphospholipid system (APS). However, its efficacy is still inconclusive. This systematic review aims to assess its efficacy and safety for patients with RCA and APS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014619DOI Listing
February 2019
1 Read

[The clinical characteristics of antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension].

Zhonghua Nei Ke Za Zhi 2019 Mar;58(3):198-201

Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.

To analyze the clinical characteristics of antiphospholipid syndrome (APS) patients with chronic thromboembolic pulmonary hypertension (CTEPH). A total of 22 APS patients with CTEPH were enrolled in our study, who were admitted in Peking Union Medical College Hospital from January 2012 to August 2018. Diagnoses were confirmed by computed tomographic pulmonary angiography (CTPA), or pulmonary angiography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2019.03.009DOI Listing

Sudden sensorineural hearing loss: A missed opportunity for treatment.

Malays Fam Physician 2018 31;13(3):29-30. Epub 2018 Dec 31.

(MD, MMED ORL-HNS) Department of Otorhinolaryngology-Head & Neck Surgery Universiti Sains Malaysia Kelantan, Malaysia.

Sudden sensorineural hearing loss (SSNHL) is an otology emergency and carries significant morbidity if the diagnosis is missed. It can present to any specialty but in our local setting the patient usually presents to primary care as it is easily accessible. We present a case of SSNHL that was initially presented to a primary care centre and the patient was reassured without any investigation being carried out. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382091PMC
December 2018
1 Read

Persistent antiphospholipid antibodies are associated with thrombotic events in ANCA-associated vasculitis: A retrospective monocentric study.

Nefrologia 2019 Feb 21. Epub 2019 Feb 21.

Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

Aim: We investigated whether persistent antiphospholipid syndrome (APLAs) at diagnosis are associated with the risk of thrombotic events during follow-up in patients with ANCA-associated vasculitis (AAV).

Methods: We retrospectively reviewed the medical records of 138 AAV patients. Thrombotic events were defined as arterial and venous thrombosis confirmed by magnetic resonance imaging, computed tomography, angiography and Doppler ultrasonography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nefro.2018.10.014DOI Listing
February 2019
1 Read

Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome.

J Autoimmun 2019 Feb 20. Epub 2019 Feb 20.

The Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine Tel-Aviv University, Israel; Department of Medicine 'B' Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Israel. Electronic address:

It is well established that the humoral immunity in antiphospholipid syndrome (APS) is presented by circulating pathogenic anti-β2GPI autoantibodies targeting mainly domain I of the β2GPI protein, playing a major role in the disease pathogenesis. Previously, we have demonstrated that treatment of experimental APS mice with tolerogenic dendritic cells loaded with domain-I was more efficient in tolerance induction than with the whole molecule or domain-V. In the current study we had orally administered a domain-I derivative of the β2GPI molecule, as a new therapeutic approach to induce oral tolerance in this mouse model of APS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2019.02.002DOI Listing
February 2019
2 Reads

Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome.

Scand J Rheumatol 2019 Feb 22:1-2. Epub 2019 Feb 22.

a Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) , IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03009742.2019.1574022DOI Listing
February 2019
2 Reads

Ischemic colitis due to antiphospholipid antibody syndrome.

Turk J Emerg Med 2019 Jan 9;19(1):36-38. Epub 2018 Oct 9.

Mashhad University of Medical Sciences, Mashhad, Iran.

Introduction: Portal system ischemia may present insidiously which may aggravates the prognosis.

Case Presentation: A 26-year old man presented with watery diarrhea and generalized abdominal pain for 3 months. On physical examination, moderate splenomegaly was noticeable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tjem.2018.10.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370907PMC
January 2019
1 Read

Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus.

Front Pharmacol 2019 6;10:82. Epub 2019 Feb 6.

Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.

New treatment options constitute unmet needs for patients diagnosed with systemic lupus erythematosus (SLE). Inhibition of the mammalian target of rapamycin (mTOR) pathway by sirolimus, a drug approved and in clinical use to prevent transplant rejection, has shown promising effects in lupus animal models as well as in patients with both antiphospholipid syndrome and SLE. Sirolimus inhibits antigen-induced T cell proliferation and increases the number of circulating regulatory T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372521PMC
February 2019
2 Reads

High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening.

Thromb Res 2019 Feb 11;176:67-73. Epub 2019 Feb 11.

Krakow Center for Medical Research and Technology, John Paul II Hospital, Krakow, Poland; Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. Electronic address:

Introduction: Thrombophilia screening has limited detection efficiency. We assessed the detection rate when a standardized approach to thrombophilia-screened outpatients was used.

Methods: We analyzed 1185 patients (36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2019.02.008DOI Listing
February 2019
2 Reads

[Genetic causes of stroke in young patients].

Zh Nevrol Psikhiatr Im S S Korsakova 2019 ;119(1):102-109

Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russia.

The paper addresses genetic causes of stroke: MELAS, antiphospholipid syndrome, CADASIL, Fabry disease. The etiology and pathogenesis, symptoms, diagnosis, treatment methods of these diseases are described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/jnevro2019119011102DOI Listing
January 2019
2 Reads

Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.

Arthritis Res Ther 2019 Feb 18;21(1):62. Epub 2019 Feb 18.

Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, 171 76, Stockholm, Sweden.

Background: Previous studies and own clinical observations of patients with systemic lupus erythematosus (SLE) suggest that SLE harbors distinct immunophenotypes. This heterogeneity might result in differences in response to treatment in different subgroups and obstruct clinical trials. Our aim was to understand how SLE subgroups may differ regarding underlying pathophysiology and characteristic biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1836-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378708PMC
February 2019
1 Read

Thrombophilia, risk factors and prevention.

Expert Rev Hematol 2019 Mar 26;12(3):147-158. Epub 2019 Feb 26.

a Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine (DIMED) , Padova University Hospital , Padova , Italy.

Introduction: Fifty-three years after the first description of an inherited prothrombotic condition (antithrombin deficiency), our knowledge on hereditary and acquired causes of hypercoagulability that can predispose carriers to venous thromboembolism (VTE) has greatly improved. Areas covered: Main causes of hereditary thrombophilia are summarized alongside new prothrombotic mutations recently discovered. The main causes of acquired thrombophilia, and namely, antiphospholipid antibody syndrome and hyperhomocysteinemia, are also discussed together with other common acquired prothrombotic states characterized by an increase of procoagulant factors and/or a decrease of natural anticoagulants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583555DOI Listing
March 2019
1 Read

Juvenile polyautoimmunity in a rheumatology setting.

Autoimmun Rev 2019 Feb 14. Epub 2019 Feb 14.

Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.. Electronic address:

Overt polyautoimmunity (PolyA) corresponds to the presence of more than one well-defined autoimmune disease (AD) manifested clinically in a single patient. The current study aimed to describe the main characteristics of juvenile PolyA in a pediatric rheumatology setting and analyze the chronological aspects, index cases, familial autoimmunity, and clustering pattern. This was a cross-sectional and multicenter study in which 313 children with overt PolyA were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.006DOI Listing
February 2019
2 Reads
7.933 Impact Factor

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.

Autoimmun Rev 2019 Feb 15. Epub 2019 Feb 15.

Obstetrics and Gynaecology Department, High Risk Unit, Vall d'Hebron University Hospital, Universitat Autonoma, Barcelona, Spain.

Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS).

Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.006DOI Listing
February 2019
1 Read

Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia.

Autoimmun Rev 2019 Feb 14. Epub 2019 Feb 14.

Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo (USP), Brazil.

Objective: Recently, two studies demonstrated that a relevant percentage of primary antiphospholipid syndrome (PAPS) patients had an upregulation of interferon (IFN) genes. However, 20%-28% of these patients had anti-dsDNA, a highly specific systemic lupus erythematosus (SLE) autoantibody. This study aimed to determine the prevalence of the type I IFN signature in the peripheral blood mononuclear cells of PAPS patients without specific SLE autoantibodies and search for its clinical associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.004DOI Listing
February 2019
2 Reads

Prevalence of myocardial infarction with non-obstructive coronary arteries (MINOCA) amongst acute coronary syndrome in patients with antiphospholipid syndrome.

Int J Cardiol Heart Vasc 2019 Mar 1;22:148-149. Epub 2019 Feb 1.

Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, United States of America.

Antiphospholipid antibody syndrome (APLS) is well known to cause thrombotic events and premature atherosclerosis leading to coronary artery occlusion. The association of non-thrombotic acute myocardial infarctions (AMI) with APLS is not as clearly delineated. The objective of this study was to determine the relative prevalence of myocardial infarction with non obstructive coronary arteries (MINOCA) compared to MI from vaso-occlusive disease amongst patients with known APLS at our institution. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23529067183015
Publisher Site
http://dx.doi.org/10.1016/j.ijcha.2018.12.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360345PMC
March 2019
8 Reads

The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.

Clin Chem Lab Med 2019 Feb 14. Epub 2019 Feb 14.

Institute of Cardiology, Jagiellonian University Medical College and John Paul II Hospital, Krakow, Poland.

Background Direct oral anticoagulants (DOACs) cause false positive lupus anticoagulant (LA) results. We assessed the impact of DOAC-Stop, reversing in vitro effects of DOACs, on LA testing in anticoagulated patients. Methods We assessed 75 venous thromboembolism patients aged 44. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2018-1197DOI Listing
February 2019
4 Reads

Outcomes of coronary artery revascularization procedures in patients with antiphospholipid syndrome.

Cardiovasc Revasc Med 2019 Jan 25. Epub 2019 Jan 25.

Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY 10467, United States of America.

Background: Published data on the outcome of coronary artery revascularization in patients with antiphospholipid syndrome (APS) are limited. Because APS is associated with a high rate of arterial thrombosis, there is concern that coronary revascularization in this group may be complicated by increased need for repeat revascularization. We aimed to determine the incidence and timing of repeat revascularization performed in patients with APS undergoing percutaneous coronary interventions (PCI) or coronary artery bypass grafting (CABG). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carrev.2019.01.027DOI Listing
January 2019
1 Read

Use of Intravenous Immunoglobulin Therapy at Unconventional Doses in Refractory Fulminant Systemic Lupus Erythematosus.

Eur J Case Rep Intern Med 2018 27;5(9):000934. Epub 2018 Sep 27.

Rare Diseases and Periodic Fevers Research Centre, Department of Internal Medicine, Agostino Gemelli University Hospital Foundation, Catholic University of the Sacred Heart, Rome, Italy.

The use of human intravenous immunoglobulins (IVIg) in systemic lupus erythematosus (SLE) currently relies on evidence from small case series and is mainly regarded as an off-label strategy in cases that are refractory to conventional therapies or poorly controlled with high doses of corticosteroids. Standard dosage regimens typically entail the administration of a total amount of 2 g/kg of IVIg divided into five consecutive days in order to minimize the risk of severe adverse events. We herein describe the case of a 28-year-old woman with a known history of antiphospholipid syndrome (APS) who was admitted to our hospital following fulminant onset of SLE in spite of ongoing immunosuppressive therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346821PMC
September 2018
2 Reads

Transcranial Doppler findings in antiphospholipid syndrome.

Lupus 2019 Feb 12:961203319828833. Epub 2019 Feb 12.

1 Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil.

Introduction: Transcranial Doppler is a method that enables the assessment of different cerebral hemodynamic parameters. It also allows for the evaluation of the presence of right-to-left circulation shunts (RLS) and for the detection of microembolic signals (MESs), which might be associated with an increased risk of cerebrovascular events. For instance, the presence of MESs on transcranial Doppler in patients with systemic lupus erythematous (SLE) and antiphospholipid syndrome (APS) is associated with an increased risk of stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319828833DOI Listing
February 2019
1 Read

Multimodality imaging in antiphospholipid syndrome.

Eur Heart J Cardiovasc Imaging 2019 Feb 11. Epub 2019 Feb 11.

Department of Cardiology, Carmel Medical Center, Haifa, Israel; Faculty of Medicine, Technion, Israel institute of Medicine, 7 Michal St., Haifa, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ehjci/jez020DOI Listing
February 2019
1 Read

Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Curr Opin Rheumatol 2019 Mar 1. Epub 2019 Mar 1.

Division of Rheumatology, Department of Internal Medicine, University of Michigan.

Purpose Of Review: Although antiphospholipid syndrome (APS) is best known for conveying increased risk of thrombotic events and pregnancy morbidity, thrombocytopenia is also recognized as a common association. In this review, we will explore the relationship between thrombocytopenia and APS, highlighting our evolving understanding - and persistent knowledge gaps - through clinically oriented questions and answers.

Recent Findings: A history of thrombocytopenia likely portends a more severe APS phenotype (including increased risk of thrombosis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000595DOI Listing
March 2019
1 Read

Damage indices in rheumatic diseases: A systematic review of the literature.

Semin Arthritis Rheum 2019 Jan 17. Epub 2019 Jan 17.

The University of Melbourne, St Vincent's Hospital, Melbourne, Australia; St Vincent's Hospital, Melbourne, Australia. Electronic address:

Objective: To review the current literature, and evaluate the psychometric properties of disease damage indices in rheumatic diseases.

Methods: A search of Medline, EMBASE, and Cochrane Library databases was performed to June 2018 to identify damage indices in all systemic rheumatic diseases. Articles were included in a systematic review if indices were composite (multi-organ) in nature and if adequate detail on methodology was described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2019.01.007DOI Listing
January 2019
2 Reads

Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus.

J Proteome Res 2019 Mar 18;18(3):1208-1217. Epub 2019 Feb 18.

Computational Life Science Cluster (CLiC), Department of Chemistry , Umeå University , 901 87 Umeå , Sweden.

The aim of this study was to evaluate how the cytokine profiles differed between autoantibody based subgroups of systemic lupus erythematosus (SLE). SLE is a systemic autoimmune disease, characterized by periods of flares (active disease) and remission (inactive disease). The disease can affect many organ systems, e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jproteome.8b00811DOI Listing
March 2019
4 Reads

New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism.

Med J Aust 2019 Mar 10;210(5):227-235. Epub 2019 Feb 10.

Monash University, Melbourne, VIC.

Introduction: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disease and, globally, more than an estimated 10 million people have it yearly. It is a chronic and recurrent disease. The symptoms of VTE are non-specific and the diagnosis should actively be sought once considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5694/mja2.50004DOI Listing
March 2019
3 Reads
4.089 Impact Factor

Tumid lupus erythematosus-like pseudovasculitic lesions in catastrophic antiphospholipid syndrome.

JAAD Case Rep 2019 Feb 31;5(2):198-200. Epub 2019 Jan 31.

Department of Dermatology, University of California, Davis, Sacramento, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357785PMC
February 2019
1 Read

Apoptosis in patients with primary antiphospholipid antibody syndrome.

Int J Rheum Dis 2019 Feb 6. Epub 2019 Feb 6.

Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan.

Aim: Dysregulated apoptosis has been implicated in autoimmune diseases. In the present study, we investigated the apoptosis-related cytokines and apoptosis in patients with primary antiphospholipid syndrome (pAPS).

Method: We prospectively recruited 12 pAPS patients, 17 antiphospholipid antibody (APA)-positive systemic lupus erythematosus (SLE) patients without APS manifestations (APA SLE), 13 SLE patients with secondary APS (APS SLE) and 10 healthy controls (HCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13468DOI Listing
February 2019
2 Reads

Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders.

Indian J Clin Biochem 2019 Jan 10;34(1):95-100. Epub 2017 Nov 10.

Department of Pediatric Immunology, Faculty of Medicine, Ege University, 35040 Bornova, Izmir, Turkey.

Anti-beta-2-glycoprotein I antibodies (anti-β2GPI) which are the main antiphospholipid antibodies that characterize the autoimmune "antiphospholipid syndrome" are pathogenic and are contributing to thrombosis. We aimed to evaluate the presence and the diagnostic importance of these antibodies in children with different rheumatologic diseases with or without thrombosis risk. A total of 100 children with different rheumatologic diseases evaluated retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12291-017-0711-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346611PMC
January 2019
1 Read

Antiphospholipid syndrome and neurofibromatosis type I: a coincidence or new association?

Arq Bras Oftalmol 2019 Mar-Apr;82(2):155-157

Department of Neuro-radiology, Sheikh Khalifa Hospital, Abu Dhabi, UAE.

Numerous studies have reported on structural vascular anomalies and ischemia associated with neurofibromatosis type 1 that are thought to stem from dysfunction of neurofibromin, the neurofibromatosis type 1 protein. Documented cases of associated antiphospholipid syndrome fulfilling the accepted diagnostic criteria are exceptionally rare, with only three cases reported in the literature. Here, we report on a patient with neurofibromatosis type 1 and a history of spontaneous abortions presenting with sudden vision loss in the right eye and swelling of the optic nerve head. Read More

View Article

Download full-text PDF

Source
http://www.gnresearch.org/doi/10.5935/0004-2749.20190032
Publisher Site
http://dx.doi.org/10.5935/0004-2749.20190032DOI Listing
August 2018
12 Reads

Influence of Hormones on Sjögren's Syndrome.

Curr Pharm Des 2018 ;24(35):4167-4176

Department of Prosthodontics, Dental Hospital, Jilin University, Changchun, Jilin 130021, China.

Sjögren's syndrome (SS) is an immune system oral disorder that is characterized generally by dry mouth and eyes. In this review, SS classification, presentation and pathogenesis are briefly discussed. Moreover, the epidemiology of SS regarding sex, age and association with other complications are also presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612824666181010153536DOI Listing
January 2018
2 Reads